Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SMART LAB LLC

NPI: 1770980062 · PALM BEACH GARDENS, FL 33410 · Clinical Medical Laboratory · NPI assigned 12/02/2014

$29K
Total Medicaid Paid
475
Total Claims
136
Beneficiaries
3
Codes Billed
2018-01
First Month
2018-04
Last Month

Provider Details

Authorized OfficialWAYNE, JUSTIN (CHIEF OPERATING OFFICER)
NPI Enumeration Date12/02/2014

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 475 $29K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 234 64 $19K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 229 60 $9K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 12 12 $0.00